This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 15
th Annual BIO CEO & Investor Conference, which will be held at the Waldorf Astoria Hotel in New York City.
Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Monday, February 11
th at 11:30 am EST in the East Foyer Room.
Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon
1 is being studied in clinical trials for 17 vaccine indications. They include:
Phase 3: GSK's RTS,S for malaria 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected melanoma 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected non-small cell lung cancer 2
Phase 3: GSK's HZ/su for shingles 2
Phase 2: Janssen's ACC-001 for Alzheimer's disease
Agenus pipeline programs include:
Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes
Phase 2: Prophage Series G-100 for newly diagnosed glioma
Phase 2: Prophage Series G-200 for recurrent glioma
Saponin Platform: QS-21 Stimulon®Adjuvant
Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
Heat Shock Protein Platform: Recombinant Series HerpV
HerpV is the most advanced HSV-2 therapeutic vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.